BioNTech SE
NASDAQ:BNTX
BioNTech SE
NASDAQ:BNTX
Price:
92.51 USD
0.25%
Updated:
May 15, 2024
BioNTech SE
Cash from Operating Activities
|
BioNTech SE
Cash from Operating Activities Peer Comparison
Comparables:
MOR
CVAC
IMTX
BIO
FYB
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
BioNTech SE
NASDAQ:BNTX
|
Cash from Operating Activities
€5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Cash from Operating Activities
-€298.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Cash from Operating Activities
-€267.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Cash from Operating Activities
€18.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Cash from Operating Activities
-€2.7m
|
CAGR 3-Years
46%
|
CAGR 5-Years
44%
|
CAGR 10-Years
9%
|
|
|
Formycon AG
XETRA:FYB
|
Cash from Operating Activities
-€9.8m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is BioNTech SE's Cash from Operating Activities?
Cash from Operating Activities
5.4B
EUR
5.4B
EUR
Based on the financial report for Dec 31, 2023, BioNTech SE's Cash from Operating Activities amounts to 5.4B EUR.
What is BioNTech SE's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 1Y
-60%
-60%
Over the last year, the Cash from Operating Activities growth was -60%.
You don't have any saved screeners yet
